This reference monoclonal antibody, based on the Genentech patent for anti-TAT226, is used in targeted cancer therapies, particularly in the treatment of solid tumors expressing the TAT226 antigen. It functions by binding selectively to tumor-associated TAT226, enabling precise delivery of cytotoxic agents when conjugated to drug payloads, thus minimizing damage to healthy tissues. It is also employed in diagnostic imaging to detect TAT226-positive tumors. Its high specificity supports use in clinical research for monitoring treatment response and disease progression. Additionally, it serves as a critical tool in developing antibody-drug conjugates (ADCs) and evaluating target engagement in preclinical studies, as well as in bioassays such as ELISA and immunohistochemistry.